Targeted degradation of specific TEAD paralogs by small molecule degraders

被引:0
|
作者
Chen, Hui [2 ]
Gridnev, Artem [1 ,3 ]
Schlamowitz, Netanya [1 ,4 ]
Hu, Wanyi [2 ]
Dey, Kuntala [2 ]
Zheng, Guangrong [2 ]
Misra, Jyoti R. [1 ]
机构
[1] SUNY Stony Brook, Sch Med, Dept Pharmacol Sci, Stony Brook, NY 11794 USA
[2] Univ Florida, Coll Pharm, Dept Med Chem, Gainesville, FL 32610 USA
[3] Oregon Hlth & Sci Univ, Grad Sch Biomed Sci, Portland, OR USA
[4] Univ Texas Southwestern Med Ctr, Grad Sch Biomed Sci, Dallas, TX USA
关键词
HIPPO PATHWAY; PROTEIN-DEGRADATION; INHIBITOR; YAP/TAZ; EXPRESSION; DISCOVERY; DESIGN;
D O I
10.1016/j.heliyon.2024.e37829
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The transcription factors, TEAD1-4 together with their co-activator YAP/TAZ function as key downstream effectors of the Hippo pathway. Hyperactivation of TEAD-YAP/TAZ activity is observed in many human cancers. TEAD1-4 possess distinct physiological and pathological functions, with conserved sequences and structures. Targeting specific isoforms within TEAD1-4 can serve as valuable chemical probes for investigating TEAD-related functions in both development and diseases. We report the TEAD-targeting proteolysis targeting chimera (PROTAC), HC278, which achieves effective and specific targeting of TEAD1 and TEAD3 at low nanomolar doses while weakly degrading TEAD2 and TEAD4 at higher doses. Proteomic analysis of >6000 proteins confirmed their highly selective TEAD1 and TEAD3 degradation. Consistently, HC278 can suppress the proliferation of YAP-dependent NCI-H226 mesothelioma cells. Mechanistic exploration revealed that both CRBN and proteasome systems are involved in the TEAD degradation induced by HC278. Moreover, RNA-seq and Gene Set Enrichment Analysis (GSEA) revealed that the YAP signature genes such as CTGF, CYR61, and ANKRD1 are significantly downregulated by HC278 treatment. Overall, HC278 serves as a valuable chemical tool for unraveling the intricate biological roles of TEAD1 and TEAD3 and holds the potential as a lead compound for developing targeted therapy for TEAD1/3-driven pathologies.
引用
收藏
页数:24
相关论文
共 50 条
  • [21] Small molecule modulators of protein-protein interactions and targeted protein degradation
    Buckley, Dennis
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
  • [22] Targeted degradation of PARP14 Using a heterobifunctional small molecule.
    Wigle, Tim
    Ren, Yue
    Molina, Jennifer
    Blackwell, Danielle
    Schenkel, Laurie
    Swinger, Kerren
    Cheug, Anne
    Abo, Ryan
    Minissale, Elena
    Lu, Alvin
    Majer, Christina
    Church, William
    Dorsey, Bryan
    Niepel, Mario
    Perl, Nicholas
    Kuplast-Barr, Kristy
    McEachern, Kristen
    Vasbinder, Melissa
    Keilhack, Heike
    Kuntz, Kevin
    CANCER RESEARCH, 2021, 81 (13)
  • [23] Identification of a small molecule that induces targeted protein degradation of ADAR1
    Liu, Yuan
    Larsen, Mads B.
    Lin, Bo
    Kennerdell, Jason R.
    Alfaras, Irene
    Camarco, Daniel P.
    Tuncer, Ferhan
    Finkel, Toren
    Chen, Bill B.
    CANCER RESEARCH, 2023, 83 (07)
  • [24] Breaking down KRAS: small-molecule degraders for cancer therapy
    Kos, Tina
    Saur, Dieter
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2025, 10 (01)
  • [25] Biologics-based degraders - an expanding toolkit for targeted-protein degradation
    VanDyke, Derek
    Taylor, Jonathan D.
    Kaeo, Kyle J.
    Hunt, James
    Spangler, Jamie B.
    CURRENT OPINION IN BIOTECHNOLOGY, 2022, 78
  • [26] Chemo-proteomics exploration of HDAC degradability by small molecule degraders
    Xiong, Yuan
    Donovan, Katherine A.
    Eleuteri, Nicholas A.
    Kirmani, Nadia
    Yue, Hong
    Razov, Anthony
    Krupnick, Noah M.
    Nowak, Radoslaw P.
    Fischer, Eric S.
    CELL CHEMICAL BIOLOGY, 2021, 28 (10) : 1514 - +
  • [27] Targeting cancer with small-molecule pan-KRAS degraders
    Popow, Johannes
    Farnaby, William
    Gollner, Andreas
    Kofink, Christiane
    Fischer, Gerhard
    Wurm, Melanie
    Zollman, David
    Wijaya, Andre
    Mischerikow, Nikolai
    Hasenoehrl, Carina
    Prokofeva, Polina
    Arnhof, Heribert
    Arce-Solano, Silvia
    Bell, Sammy
    Boeck, Georg
    Diers, Emelyne
    Frost, Aileen B.
    Goodwin-Tindall, Jake
    Karolyi-Oezguer, Jale
    Khan, Shakil
    Klawatsch, Theresa
    Koegl, Manfred
    Kousek, Roland
    Kratochvil, Barbara
    Kropatsch, Katrin
    Lauber, Arnel A.
    Mclennan, Ross
    Olt, Sabine
    Peter, Daniel
    Petermann, Oliver
    Roessler, Vanessa
    Stolt-Bergner, Peggy
    Strack, Patrick
    Strauss, Eva
    Trainor, Nicole
    Vetma, Vesna
    Whitworth, Claire
    Zhong, Siying
    Quant, Jens
    Weinstabl, Harald
    Kuster, Bernhard
    Ettmayer, Peter
    Ciulli, Alessio
    SCIENCE, 2024, 385 (6715) : 1338 - 1347
  • [28] Optimization of a Protein-Targeted Medicine into an RNA-Specific Small Molecule
    Meyer, Samantha M.
    Tanaka, Toru
    Taghavi, Amirhossein
    Baisden, Jared T.
    Grefe, Maison
    Disney, Matthew D.
    ACS CHEMICAL BIOLOGY, 2023, 18 (11) : 2336 - 2342
  • [29] PROTAC small-molecule degraders of MDM2 protein
    Aguilar, A.
    Yang, J.
    Li, Y.
    McEachern, D.
    Przybranowski, S.
    Liu, L.
    Yang, C. Y.
    Wang, S.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E94 - E94
  • [30] Discovery of Small-Molecule Degraders for Alpha-Synuclein Aggregates
    Tong, Yichen
    Zhu, Wentao
    Chen, Jian
    Wen, Tianzhi
    Xu, Fang
    Pang, Jiyan
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (12) : 7926 - 7942